EYLEAT (aflibercept Injection) Submitted In Japan For Marketing Authorization For The Treatment Of Wet Age-Related Macular Degeneration

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced thatBayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEAT, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA for the treatment of wet AMD, central retinal vein occlusion (CRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).

Full Story →